Schilling, Uta
Henrich, Andrea
Muehlan, Clemens
Krause, Andreas
Dingemanse, Jasper http://orcid.org/0000-0002-4083-5817
Ufer, Mike
Article History
Accepted: 11 July 2021
First Online: 31 July 2021
Declarations
:
: This study was sponsored by Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
: All authors were employees and/or shareholders of Idorsia Pharmaceuticals Ltd at the time the research was performed. Daridorexant is currently in clinical development by Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
: This study was registered on clinicaltrials.gov (NCT04250506). Data are available upon request from the corresponding author.
: The study protocol was approved by the Czech health authority (SUKL) as well as an Independent Ethics Committee (Ethics Committee of CEPHA s.r.o., Pilsen, Czech Republic). It was conducted in full accordance with the principles of the Declaration of Helsinki and ICH good clinical practice guidelines.
: Each study subject provided written informed consent prior to any treatment and study-related assessment.
: US, CM, JD, and MU designed the study. AH and AK performed the concentration-QT modeling. US analyzed the data and drafted the manuscript. All authors reviewed the manuscript and approved its submission.
: Not applicable.
: Not applicable.